Pre-clinical studies of the Russian-Vietnamese drug started

02 August 2018

GMP News

Scientists of the Komi Scientific Center of the Ural Branch of the Russian Academy of Sciences and the Russian-Vietnamese Tropical Research and Technology Center have begun pre-clinical studies of the drug improving performance and resistance to stress originating from the tropical plants extracts, said Svetlana Volodina, Cand. Sc. (Biology).

“It was a mutual interest of Russian and Vietnamese scientists to find in the flora of Vietnam plants with a high content of phytoecdysteroids – substances using which it is possible to develop medications able to increase efficiency and immunity, resistance to stress and such harmful factors as, for example, radiation, which is favorable for professional longevity and longevity of people. The project is planned until 2020, now we have started preclinical studies and work on licensing documentation, ” said the biotechnologist of the Komi Science Center, which recently received the status of a federal research institute.

The scientific group under the leadership of Vladimir Volodin, Doctor of Biological Sciences, has studied biologically active plant substances (phytoecdysteroids) for more than 20 years. They analyzed hundreds of plant species from the Subpolar and Southern Urals, the North Caucasus, the Far East, and in 2015 the scientific group received an invitation from Vietnamese colleagues to conduct joint research.

During work in Vietnam, a high content of phytoecdysteroids was found in herbaceous cyathula and chaff-flower, in the leaves of the Sida Rombofolia, in bark and young leaves of the genus Vitextrees.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more